Month: April 2021

SHANGHAI, China., and GAITHERSBURG, MD, April 14, 2021 (GLOBE NEWSWIRE) — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its abstract on proprietary and highly differentiated CD73 antibody uliledlimab (also known as TJD5, or TJ004309) has been selected for detailed poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually June 4-8, 2021. Uliledlimab is a humanized CD73 antibody that works effectively as an anti-tumor agent through modulation of the tumor microenvironment by inhibiting the adenosine pathway that is implicated in tumor resistance to checkpoint immunotherapies. Uliledlimab is shown to strongly suppress tumor growth, especially...

TAMPA, FL, April 14, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — ENVIRO-SERV, INC. (OTC: EVSV) is excited to provide shareholders with several exciting updates announcing the first ever acquisition of high-quality hemp bio-mass from competing farmers looking for exit strategies to monetize their crop. Chris Trina, Enviro-Serv, Inc. Chairman and CEO, revealed that, “As we’ve tweeted lately about some updates the hemp industry is ever evolving and has been challenging to say the least. We continue to monitor very closely with our processing partners and affiliates, crude oil and flower pricing as market pricing is ever changing. Many experts believe we are, at or near, the bottom of this unforeseen hemp oil pricing decline and we look forward in monetizing our hemp farming investments over the past two years here in 2021. At the...

HOUSTON, April 14, 2021 (GLOBE NEWSWIRE) — Sharps Compliance Corp. (Nasdaq: SMED) announced today that it will release its third quarter 2021 results for the period ended March 31, 2021, before the opening of the financial markets on Wednesday, April 28, 2021. A conference call and webcast will follow at 11:00 a.m. ET, in which management will discuss the Company’s financial results, key market initiatives and business strategy. The Sharps conference call can be accessed by domestic callers by dialing (877) 407-0782. International callers may access the call by dialing (201) 689-8567. The webcast can be monitored at www.sharpsinc.com. A telephonic replay will be available through May 28, 2021. To listen to the replay, domestic callers should dial (877) 481-4010 and international callers should dial (919) 882-2331 and enter replay...

CHARLOTTE, N.C., April 14, 2021 (GLOBE NEWSWIRE) — STRONG Technical Services, Inc. (STS), a wholly-owned subsidiary of Ballantyne Strong, Inc. (NYSE American: BTN) and a leader in projection equipment sales, engineering and services, today announced the launch of its STRONG Restart initiative deploying 10 BrightNight Drive In packages across the U.S. Each package is equipped with the Company’s Preview and Northview products, which consist of a mobile projection trailer and large 40’ x 20’ inflatable screen solution. STS will offer the package to select exhibitors for one weekend at no expense, to help cinemas safely bring customers back for the Summer 2021 blockbuster season. “STRONG has been a valued partner to cinema exhibitors since 1932,” said Blake Titman, Vice President and General Manager, STRONG Technical Services. “As the...

– Data From Company’s PKU and Hunter Syndrome Gene Therapy Programs Featured in Presentations – BEDFORD, Mass., April 14, 2021 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today two presentations highlighting clinical and preclinical data from the Company’s phenylketonuria (PKU) and MPS II (Hunter syndrome) in vivo gene therapy programs, respectively, at the virtual American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. “We continue to demonstrate the breadth of our growing pipeline with expanded focus on diseases of the central nervous system,” stated Albert Seymour, Ph.D., Chief Scientific Officer of Homology Medicines. “Our AAVHSC vectors have shown the ability to target peripheral organs and the central and peripheral...

Global Trac Solutions, Inc. Makes the Move to the First State in America to Legalize Psilocybin  LAKE OSWEGO, OR, April 14, 2021 (GLOBE NEWSWIRE) — Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) the first publicly traded digital media company within the emerging sector of medicinal psychedelics, is pleased to announce the Company has relocated its executive and company headquarters from Las Vegas, NV, to the state of Oregon, which, the Company contends, has emerged in recent months as a fundamental state in the US for the development and expansion of the medicinal psychedelic industry. With the successful passage of Measure 109 last November by Oregon voters, the state is poised to become the first in the nation to develop and implement a state-regulated psilocybin therapy program for residents suffering...

NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) — WisdomTree, an exchange traded fund (“ETF”) and exchange traded product (“ETP”) sponsor, has announced its physically-backed1 Bitcoin ETP has listed on Germany’s Börse Xetra. The WisdomTree Bitcoin ETP has a total expense ratio of 0.95% and is already listed on SIX, the Swiss Stock Exchange. The listing of the WisdomTree Bitcoin ETP on Börse Xetra follows approval from the Swedish regulator to distribute this ETP across the European Union (EU). Alexis Marinof, Head of Europe, WisdomTree, said: “Passporting WisdomTree Bitcoin in the EU was the ambition since we decided to launch a cryptocurrency ETP, and the evolving regulatory landscape has made this possible. The move represents an important milestone for our best-in-class product and one which will resonate with...

Nasdaq OMX Copenhagen A/S             Nikolaj Plads 6                                        DK-1007 København K                                                                       Fondsbørsmeddelelse nr. 170/2021 14. april 2021 REFERAT af ordinær generalforsamling i Prime Office A/S, CVR-nr. 30558642 Den 14. april 2021 blev der afholdt ordinær generalforsamling i selskabet på selskabets adresse i Aarhus. Dagsordenen var følgende:Bestyrelsens beretning om selskabets virksomhed i det forløbne år. Fremlæggelse af årsrapport for 2020 med revisionspåtegning til godkendelse, herunder beslutning om decharge for bestyrelse og direktion samt godkendelse af vederlag til bestyrelsen. Vedtagelse af fordeling af overskud eller underskud efter forslag fra bestyrelsen og udbetaling af udbytte på 5 DKK pr. aktie Fremlæggelse af og vejledende afstemning...

—ORLADEYO is the first and only approved prophylactic therapy for HAE in Japan— —NHI price listing triggers $15 million milestone payment to BioCryst—    RESEARCH TRIANGLE PARK, N.C., April 14, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Japanese National Health Insurance System (NHI) has approved the addition of oral, once-daily ORLADEYO™ (berotralstat) to the NHI drug price list on April 21, 2021.   Oral, once-daily ORLADEYO was approved in Japan in January 2021 for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. ORLADEYO is the first and only prophylactic HAE medication approved in Japan. ORLADEYO will be commercialized in Japan by BioCryst’s partner, Torii Pharmaceutical Co., Ltd. Torii plans to launch ORLADEYO following...

MENLO PARK, Calif., April 14, 2021 (GLOBE NEWSWIRE) — 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that Lynn Williams, Ph.D., has been awarded the International Dupuytren Award 2021 for Basic Research. Dr. Williams is a research fellow at the Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, University of Oxford, Oxford, England, whose research is being sponsored by 180 Life Sciences. Dr. Williams won the award for her paper published in a peer-reviewed journal in 2020. The paper titled “Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300,” published in Proceedings...